Bortezomib did not improve outcomes for participants with the activated B-cell subtype of diffuse large B-cell lymphoma, which was confirmed to be enriched for expression of NF-κB target genes, or for patients with somatic mutations associated with NF-κB activation. The gene discussed is NFKB1; the disease is diffuse large B-cell lymphoma.